论文部分内容阅读
目的评价Ag85B-卡介苗重组疫苗对结核病的预防及治疗效果。方法将小鼠随机分为6组,A、B、C为预防组,D、E、F为治疗组,A、D组为Ag85B-卡介苗重组疫苗免疫组,B、E组为BCG免疫组,C、F组为生理盐水对照组。通过研究各组小鼠在实验中的血清抗体水平、细胞免疫功能等指标以及体重变化、半数死亡时间、2个月死亡率、大体病变等,评价Ag85B-卡介苗重组疫苗在小鼠结核分枝杆菌感染的预防及治疗成效。结果在注射结核分枝杆菌后,各组小鼠体重平均增长明显减慢,C、F组增长最慢。A、B、D、E组与C、F组相比能延长半数死亡时间,降低一定时间内的死亡率。小鼠脏器大体病变各组之间无显著差别。A、B、D、E 4组小鼠,肺脏的结核分枝杆菌生长培养最低稀释度集中在105,肝脏、脾脏结核分枝杆菌生长培养最低稀释度集中在104。C、F组小鼠,肺脏结核分枝杆菌生长的培养最低稀释度集中在106,肝脏、脾脏结核分枝杆菌生长的培养最低稀释度集中在105。各组间的抗体检测及淋巴细胞增殖实验结果无显著差别。结论 Ag85B-卡介苗重组疫苗与卡介苗对于结核分枝杆菌感染的预防作用无显著区别,Ag85B-卡介苗重组疫苗和卡介苗对结核病无明显的治疗效果。
Objective To evaluate the preventive and therapeutic effects of recombinant Ag85B-BCG vaccine on tuberculosis. Methods The mice were randomly divided into 6 groups: A, B, C for the prophylaxis group, D, E, F for the treatment group, A, D group for the Ag85B- BCG recombinant vaccine immune group, B, E group BCG immune group, Group C and F were saline control group. By studying the level of serum antibody, cellular immune function, body weight, half-life, 2-month mortality and general pathological changes in mice, the recombinant Ag85B-BCG vaccine was evaluated in mice with Mycobacterium tuberculosis Infection prevention and treatment effectiveness. Results After the injection of Mycobacterium tuberculosis, the average body weight of mice in each group slowed down significantly, while the growth in groups C and F was the slowest. A, B, D, E group and C, F group can extend half the time of death, reduce the mortality rate within a certain period of time. There was no significant difference between the groups of mouse organ lesions in all groups. The minimum dilutions of Mycobacterium tuberculosis in lungs of group A, B, D, and E 4 were 105, and the minimum dilution of M. tuberculosis in liver and spleen was 104. The minimum dilution of culture of M. tuberculosis in group C and group F was concentrated at 106, and the minimum dilution of culture of M. tuberculosis in liver and spleen was concentrated at 105. Antibody detection and lymphocyte proliferation test results between groups no significant difference. Conclusion There is no significant difference between the recombinant Ag85B-BCG vaccine and BCG vaccine in the prevention of Mycobacterium tuberculosis infection. The recombinant Ag85B-BCG vaccine and BCG have no significant effect on tuberculosis.